Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Vaccine

Volumn 31, Issue 7, 2013, Pages 1113-1116

  Hong, Eva ^a   Giuliani, Marzia Monica ^b   Deghmane, Ala Eddine ^a   Comanducci, Maurizio ^b   Brunelli, Brunella ^b   Dull, Peter ^b   Pizza, Mariagrazia ^b   Taha, Muhamed Kheir ^a  

^a INSTITUT PASTEUR   (France)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

African meningitis belt; Epidemics; Neisseria meningitidis; Serogroup X; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AFRICA; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOOD SAMPLING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HUMAN; HUMAN TISSUE; INFANT; INFECTION CONTROL; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; AFRICA; ANTIGENS, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; DISEASE OUTBREAKS; FEMALE; FRANCE; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; HUMANS; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS;

EID: 84872606298     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.022     Document Type: Article

References (28)

1. Lapeyssonnie L. Cerebrospinal Meningitis in Africa. Bull World Health Organ 1963, 28(Suppl.):1-114.
2. Zimmer S.M., Stephens D.S. Meningococcal conjugate vaccines. Expert Opin Pharmacother 2004, 5(4):855-863.
3. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Mainassara H.B., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44(5):657-663.
4. Taha M.K., Parent Du Chatelet I., Schlumberger M., Sanou I., Djibo S., De Chabalier F., et al. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002, 40(3):1083-1084.
5. Djibo S., Nicolas P., Alonso J.M., Djibo A., Couret D., Riou J.Y., et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003, 8(12):1118-1123.
6. Traore Y., Njanpop-Lafourcade B.M., Adjogble K.L., Lourd M., Yaro S., Nacro B., et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso: 2002-2005. Clin Infect Dis 2006, 43(7):817-822.
7. Gagneux S., Wirth T., Hodgson A., Ehrhard I., Morelli G., Kriz P., et al. Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis 2002, 8(5):462-466.
8. Gagneux S.P., Hodgson A., Smith T.A., Wirth T., Ehrhard I., Morelli G., et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002, 185(5):618-626.
9. Leimkugel J., Forgor A.A., Dangy J.P., Pfluger V., Gagneux S., Hodgson A., et al. Genetic diversification of Neisseria meningitidis during waves of colonization and disease in the meningitis belt of sub-Saharan Africa. Vaccine 2007, 25(Suppl. 1):A18-A23.
10. Leimkugel J., Hodgson A., Forgor A.A., Pfluger V., Dangy J.P., Smith T., et al. Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 2007, 4(3):e101.
11. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(24):2293-2304.
12. Eckhardt M., Muhlenhoff M., Bethe A., Koopman J., Frosch M., Gerardy-Schahn R. Molecular characterization of eukaryotic polysialyltransferase-1. Nature 1995, 373(6516):715-718.
13. Steenbergen S.M., Vimr E.R. Functional relationships of the sialyltransferases involved in expression of the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C. J Biol Chem 2003, 278(17):15349-15359.
14. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(29):10834-10839.
15. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107(45):19490-19495.
16. Delrieu I., Yaro S., Tamekloe T.A., Njanpop-Lafourcade B.M., Tall H., Jaillard P., et al. Emergence of Epidemic Neisseria meningitidis serogroup X Meningitis in Togo and Burkina Faso. PLoS ONE 2011, 6(5):e19513.
17. Pajon R., Fergus A.M., Koeberling O., Caugant D.A., Granoff D.M. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011, 5(9):e1302.
18. Abdillahi H., Poolman J.T. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb Pathog 1988, 4(1):27-32.
19. Harrison O.B., Brueggemann A.B., Caugant D.A., Van Der Ende A., Frosch M., Gray S., et al. Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology 2011, 157(Pt 8):2181-2195.
20. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA: a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195(11):1445-1454.
21. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
22. Plikaytis B.D., Stella M., Boccadifuoco G., Detora L.M., Agnusdei M., Santini L., et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS: a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012, 19(10):1609-1617.
23. Santos G.F., Deck R.R., Donnelly J., Blackwelder W., Granoff D.M. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001, 8(3):616-623.
24. Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B112-B116.
25. Bundle D.R., Jennings H.J., Kenny C.P. Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation. J Biol Chem 1974, 249(15):4797-4801.
26. Xie O., Bolgiano B., Gao F., Lockyer K., Swann C., Jones C., et al. Characterization of size: structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine 2012, 30(40):5812-5823.
27. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. J Am Med Assoc 1999, 281(16):1520-1527.
28. Caron F., Du Chatelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11(6):455-463.